share_log

Citigroup Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $150

Benzinga ·  May 3 18:02

Citigroup analyst David Hoang maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral and raises the price target from $140 to $150.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment